The present invention relates to ultrasonic wireless implantable devices. More particularly, the present invention relates to attaching a piezoelectric crystal to a substrate of an ultrasonic wireless implantable device in a manner that reduces energy loss due to anchor loss.
Acoustic links for medical implants have gained attention primarily because they provide a route to wireless deep tissue systems. The miniaturization of the implants is often another key research goal in these efforts, nominally because smaller implants result in less acute, and possible chronic, tissue damage. Implant size in acoustic systems is limited in part by the onboard piezoelectric bulk crystal used for power harvesting and data communication.
Piezoelectric crystals serve as a critical component in the construction of ultrasonic wireless implantable devices; these crystals convert mechanical (acoustic) energy into electrical energy and vice versa by the piezoelectric effect. Millimeter-scale ultrasonic wireless implantable devices consist of at least a piezoelectric crystal and an integrated circuit (IC), where the piezoelectric crystal is used to power the IC and communicate with an external transceiver. Recently, many researchers in the bioelectronics field have focused on interrogating these devices implanted in deep areas of the body. A key challenge to operate these devices at centimeter-scale depths in the body is to deliver enough ultrasound energy to an implant without exceeding FDA-regulated safe power limits. In particular, miniaturization of the piezocrystal can degrade system power transfer efficiency and data transfer reliability.
A way to overcome this challenge is to maximize acoustic-to-electrical power conversion efficiency of the piezoelectric crystal. Existing ultrasonic implantable devices suffer from low acoustic-to-electrical power conversion efficiency of the piezoelectric crystal which is mainly limited by mechanical quality factor of the piezoelectric crystal, as the power conversion efficiency of the piezoelectric crystal is directly proportional to its mechanical quality factor (Q). Generally speaking, the piezoelectric crystal needs to have very low energy loss to achieve a high mechanical quality factor.
One source of energy loss in a piezoelectric crystal is “anchor loss”—a loss in vibration energy generated by the piezoelectric crystal due to “anchoring” the crystal to the substrate to which it is attached.
The present disclosure provides a new method for packaging the implant piezocrystal that maximizes power harvesting efficiency (q) and information transfer across the acoustic link. The method relies on placing anchors to the piezo regions where the vibrational mode displacement is zero. In particular, described herein are ultrasonic wireless implantable devices having a piezoelectric crystal attached to the substrate of the ultrasonic wireless implantable device via electrodes in a manner that reduces vibration or oscillation energy loss due to anchor loss. In one aspect, an implantable device is provided, comprising: a substrate; an integrated circuit attached to the substrate; and an ultrasonic transducer configured to receive ultrasonic waves that power the integrated circuit, wherein the ultrasonic transducer is attached to the substrate via one or more electrodes, and wherein the total electrode surface area in contact with the ultrasonic transducer is smaller than the surface area of a face of the ultrasonic transducer to which the one or more electrodes are attached.
In some embodiments, the one or more electrodes are each positioned at a respective corner of the face of the ultrasonic transducer to which the one or more electrodes are attached. In some embodiments, the one or more electrodes are each positioned at an edge of the face of the ultrasonic transducer to which the one or more electrodes are attached. In some embodiments, the one or more electrodes comprise a single electrode positioned at a center of the face of the ultrasonic transducer to which the single electrode is attached.
In some embodiments, the one or more electrodes include an electrode having an opening between the face of the ultrasonic transducer and the substrate.
In some embodiments, the ultrasonic transducer has a cubic shape. In some embodiments, the ultrasonic transducer has a rectangular prism shape. In some embodiments, the face of the ultrasonic transducer to which the one or more electrodes are attached has a rectangular shape.
In some embodiments, a ratio of a length of each of the one or more electrodes to a length of the face of the ultrasonic transducer to which the one or more electrodes are attached is less than 0.1. In some embodiments, a ratio of a length of each of the one or more electrodes to a length of the face of the ultrasonic transducer to which the one or more electrodes are attached is less than 0.2.
In some embodiments, the ultrasonic transducer is further configured to emit an ultrasonic backscatter.
In some embodiments, the ultrasonic transducer is configured to receive the ultrasonic waves from an interrogator comprising one or more additional ultrasonic transducers.
In some embodiments, the ultrasonic transducer is a bulk piezoelectric transducer.
In some embodiments, the implantable device is implanted in a subject. In some embodiments, the subject is a human. In some embodiments, the subject is an animal or a plant.
In some embodiments, the implantable device is about 5 mm or less in length in the longest dimension. In some embodiments, the implantable device has a volume of about 5 mm or smaller. In some embodiments, the implanted device is at least partially encapsulated by a biocompatible material.
In another aspect, a system comprising one or more of such implantable devices is provided, as well as an interrogator comprising one or more ultrasonic transducers configured to transmit ultrasonic waves to the one or more implantable devices or receive ultrasonic backscatter from the one or more implantable devices.
In some embodiments, the interrogator comprises one or more ultrasonic transducer arrays, wherein each transducer array comprises two or more ultrasonic transducers.
In some embodiments, the system comprises a plurality of implantable devices.
In some embodiments, the interrogator is configured to beam steer transmitted ultrasonic waves to alternatively focus the transmitted ultrasonic waves on a first portion of the plurality of implantable devices or focus the transmitted ultrasonic waves on a second portion of the plurality of implantable devices.
In some embodiments, the interrogator is configured to simultaneously receive ultrasonic backscatter from at least two implantable devices.
In some embodiments, the interrogator is configured to transit ultrasonic waves to the plurality of implantable devices or receive ultrasonic backscatter from the plurality of implantable devices using time division multiplexing, spatial multiplexing, or frequency multiplexing.
In some embodiments, the interrogator is configured to be wearable by a subject.
The miniaturization of medical implants to sub-mm dimensions can lead to reduced tissue damage and reduced long-term impact of the implant on surrounding tissue. A growing body of bioelectronics research has focused on developing implantable wireless systems based on sub-mm-sized implants with wide applicability in tissue for both therapies and diagnostics. Most wireless systems rely on electromagnetic (EM) waves for wireless power and data transfer; however, coupling EM waves to sub-mm implants becomes severely inefficient within tissue. Ultrasound has recently emerged as an attractive alternative to EM, to efficiently power and communicate with tiny (sub-mm3) implants deep in tissue (>5 cm).
Ultrasound-based systems employ an implant and an external transceiver outside the body; the external transceiver contains a piezoelectric transducer driven by electronics. This transducer establishes an acoustic link to the implant. The implant consists of at least a piezocrystal and an electrical component, such as an integrated circuit; the piezo harvests acoustic energy and allows for encoding information in the acoustic waves reflected from itself (a process called “backscatter modulation”). The use of backscatter modulation to transmit uplink data from inside to the outside of the body does not require active power to initiate data transmission, potentially eliminating the need for an external capacitor, thereby enabling the design of ultra-small implants.
Recently, many researchers in the bioelectronics field have focused on interrogating these devices implanted in deep areas of the body. A key challenge to operate these devices at centimeter-scale depths in the body is to deliver enough ultrasound energy to an implant without exceeding FDA-regulated safe power limits. Moreover, the size of ultrasonic implants relying on backscatter modulation is limited by the piezo as miniaturization can degrade both power transfer efficiency and data transfer reliability of the acoustic link in tissue. A common approach to this problem is to optimize the system components, such as piezo geometry, piezo material properties, and the size and focusing ability of the external transducer.
A way to overcome these challenges is to maximize acoustic-to-electrical power conversion efficiency of the piezoelectric crystal. Existing ultrasonic implantable devices suffer from low acoustic-to-electrical power conversion efficiency of the piezoelectric crystal which is mainly limited by mechanical quality factor of the piezoelectric crystal, as the power conversion efficiency of the piezoelectric crystal is directly proportional to its mechanical quality factor (Q). Generally speaking, the piezoelectric crystal needs to have very low energy loss to achieve a high mechanical quality factor.
One source of energy loss in a piezoelectric crystal is “anchor loss”—a loss in vibration/oscillation energy generated by the piezoelectric crystal due to “anchoring” the piezoelectric crystal to the substrate to which it is attached.
The present disclosure provides techniques for attaching a piezoelectric crystal to a substrate of an ultrasonic wireless implantable device in a manner that reduces anchor loss. In particular, the present application provides a solution that is based on the packaging of the implant piezo. The approach provided herein relies on positioning the anchors on the implant package at the piezo regions, where the displacement of a vibrational mode of interest is nearly zero. This approach enables reducing anchor loss that causes energy loss through the substrate, maximizing the piezo quality factor. The approach provided herein also improves system coupling (κ2). A piezo with higher Q and κ2 achieves higher power harvesting efficiency and backscatter amplitude modulation depth at resonance, maximizing system acoustic power and data link efficiency, thereby enabling the miniaturization of ultrasonic implants.
A first study was performed investigating anchor loss causing energy loss through the substrate where the piezoelectric crystal is attached. Specifically, the effects of substrate characteristics—substrate material with different stiffness and thicknesses and attachment configuration of the piezoelectric crystal and substrate—were investigated in the study. Initial study results demonstrate that anchor loss can be significantly reduced by using a thin substrate with low stiffness and small electrodes attaching the piezoelectric crystal to the substrate. In particular, anchor loss can be reduced when these electrodes are positioned to align with the corners of the piezoelectric crystal, the edges of the piezoelectric crystal, or the center of the piezoelectric crystal. Furthermore, anchor loss can be reduced when these electrodes are small compared to the size of the face of the piezoelectric crystal to which they are attached.
A second study was performed investigating piezocrystals assembled with different size anchors. The results of the study indicate that reducing the anchor size decreases anchor loss and thus improves piezo quality factor (Q). The results also show that this method improves system electromechanical coupling. A strongly coupled, high-Q piezo is demonstrated to achieve significantly higher η and superior data transfer capability at resonance, ensuring a robust acoustic link that provides a path towards the additional miniaturization of ultrasonic implants.
As used herein, “ultrasonic wireless implantable devices” may refer to devices as disclosed by any of the following documents, each of which are incorporated by reference in their entirety: U.S. Patent Application Publication No. 2019/0150883 entitled “IMPLANTS USING ULTRASONIC BACKSCATTER FOR DETECTING ELECTROPHYSIOLOGICAL SIGNALS;” U.S. Patent Application Publication No. 2019/0150882 entitled “IMPLANTS USING ULTRASONIC BACKSCATTER FOR SENSING ELECTRICAL IMPEDANCE OF TISSUE;” U.S. Patent Application Publication No. 2019/0150884 entitled “IMPLANTS USING ULTRASONIC WAVES FOR STIMULATING TISSUE;” U.S. Pat. No. 10,300,310 entitled “IMPLANTS USING ULTRASONIC BACKSCATTER FOR SENSING PHYSIOLOGICAL CONDITIONS;” U.S. Pat. No. 10,300,309 entitled “IMPLANTS USING ULTRASONIC BACKSCATTER FOR SENSING PHYSIOLOGICAL CONDITIONS;” U.S. Patent Application Publication No. 2019/0150881 entitled “IMPLANTS USING ULTRASONIC BACKSCATTER FOR RADIATION DETECTION AND ONCOLOGY;” and U.S. Pat. No. 10,118,054 entitled “IMPLANTS USING ULTRASONIC BACKSCATTER FOR SENSING PHYSIOLOGICAL CONDITIONS.”
As used herein, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise.
Reference to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
The term “miniaturized” refers to any material or component about 5 millimeters or less (such as about 4 mm or less, about 3 mm or less, about 2 mm or less, about 1 mm or less, or about 0.5 mm or less) in length in the longest dimension. In certain embodiments, a “miniaturized” material or component has a longest dimension of about 0.1 mm to about 5 mm (such as about 0.2 mm to about 5 mm, about 0.5 mm to about 5 mm, about 1 mm to about 5 mm, about 2 mm to about 5 mm, about 3 mm to about 5 mm, or about 4 mm to about 5 mm) in length. “Miniaturized” can also refer to any material or component with a volume of about 5 mm or less (such as about 4 mm 3 or less, 3 mm 3 or less, 2 mm 3 or less, or 1 mm 3 or less). In certain embodiments, a “miniaturized” material or component has a volume of about 0.5 mm to about 5 mm 3, about 1 mm 3 to about 5 mm 3, about 2 mm 3 to about 5 mm 3, about 3 mm 3 to about 5 mm 3, or about 4 mm 3 to about 5 mm 3.
A “piezoelectric transducer” is a type of ultrasonic transceiver comprising piezoelectric material. The piezoelectric material may be a crystal, a ceramic, a polymer, or any other natural or synthetic piezoelectric material.
A “non-responsive” ultrasonic wave is an ultrasonic wave with a reflectivity independent of a detected signal. A “non-responsive reflector” is a component of an implantable device that reflects ultrasonic waves such that the reflected waveform is independent of the detected signal.
The term “subject” refers to an animal.
It is understood that aspects and variations of the invention described herein include “consisting” and/or “consisting essentially of” aspects and variations.
Where a range of values is provided, it is to be understood that each intervening value between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the scope of the present disclosure. Where the stated range includes upper or lower limits, ranges excluding either of those included limits are also included in the present disclosure.
It is to be understood that one, some or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
Features and preferences described above in relation to “embodiments” are distinct preferences and are not limited only to that particular embodiment; they may be freely combined with features from other embodiments, where technically feasible, and may form preferred combinations of features.
The description is presented to enable one of ordinary skill in the art to make and use the invention and is provided in the context of a patent application and its requirements. Various modifications to the described embodiments will be readily apparent to those persons skilled in the art and the generic principles herein may be applied to other embodiments. Thus, the present invention is not intended to be limited to the embodiment shown but is to be accorded the widest scope consistent with the principles and features described herein. Further, sectional headings are provide for organizational purposes and are not to be considered limiting. Finally, the entire disclosure of the patents and publications referred in this application are hereby incorporated herein by reference for all purposes.
The interrogator can wirelessly communicate with one or more implantable devices using ultrasonic waves, which are used to power and/or operate the implantable device. The ultrasonic waves emitted by the interrogator can encode a trigger signal, which signals the implantable device to emit an electrical pulse. The interrogator includes one or more ultrasonic transducers, which can operate as an ultrasonic transmitter and/or an ultrasonic receiver (or as a transceiver, which can be configured to alternatively transmit or receive the ultrasonic waves). The one or more transducers can be arranged as a transducer array, and the interrogator can optionally include one or more transducer arrays. In some embodiments, transducers in the array can have regular spacing, irregular spacing, or be sparsely placed. In some embodiments the array is flexible. In some embodiments the array is planar, and in some embodiments the array is non-planar. In some embodiments, the ultrasound transmitting function is separated from the ultrasound receiving function on separate devices. That is, optionally, the interrogator comprises a first device that transmits ultrasonic waves to the implantable device, and a second device that receives ultrasonic backscatter from the implantable device.
In some embodiments, the interrogator can receive ultrasonic backscatter from an implantable device, such an implantable device configured to detect an electrophysiological voltage and emit ultrasonic backscatter which encodes information indicative of the detected electrophysiological voltage signal. In some embodiments, the trigger signal encoded by the ultrasonic waves emitted from the interrogator and received by the implantable device configured to emit an electrical pulse is transmitted in response to a received ultrasonic backscatter encoding information regarding the detected electrophysiological signal.
An exemplary interrogator is shown in
In some embodiments, the interrogator is implantable. An implanted interrogator may be preferred when the implantable devices are implanted in a region blocked by a barrier that does not easily transmit ultrasonic waves. For example, the interrogator can be implanted subcranially, either subdurally or supradurally. A subcranial interrogator can communicate with implantable devices that are implanted in the brain. Since ultrasonic waves are impeded by the skull, the implanted subcranial interrogator allows for communication with the implantable devices implanted in the brain. In another example, an implantable interrogator can be implanted as part of, behind or within another implanted device, such as a bone plate. The implanted interrogator can communicate with an external device, for example by EM or RF signals.
In some embodiments, the interrogator is external (i.e., not implanted). By way of example, the external interrogator can be a wearable, which may be fixed to the body by a strap or adhesive. In another example, the external interrogator can be a wand, which may be held by a user (such as a healthcare professional). In some embodiments, the interrogator can be held to the body via suture, simple surface tension, a clothing-based fixation device such as a cloth wrap, a sleeve, an elastic band, or by sub-cutaneous fixation. The transducer or transducer array of the interrogator may be positioned separately from the rest of the transducer. For example, the transducer array can be fixed to the skin of a subject at a first location (such as proximal to one or more implanted devices), and the rest of the interrogator may be located at a second location, with a wire tethering the transducer or transducer array to the rest of the interrogator.
The specific design of the transducer array depends on the desired penetration depth, aperture size, and size of the individual transducers within the array. The Rayleigh distance, R, of the transducer array is computed as:
where D is the size of the aperture and A is the wavelength of ultrasound in the propagation medium (i.e., the tissue). As understood in the art, the Rayleigh distance is the distance at which the beam radiated by the array is fully formed. That is, the pressure filed converges to a natural focus at the Rayleigh distance in order to maximize the received power. Therefore, in some embodiments, the implantable device is approximately the same distance from the transducer array as the Rayleigh distance.
The individual transducers in a transducer array can be modulated to control the Rayleigh distance and the position of the beam of ultrasonic waves emitted by the transducer array through a process of beamforming or beam steering. Techniques such as linearly constrained minimum variance (LCMV) beamforming can be used to communicate a plurality of implantable devices with an external ultrasonic transceiver. See, for example, Bertrand et al., Beamforming Approaches for Untethered, Ultrasonic Neural Dust Motes for Cortical Recording: a Simulation Study, IEEE EMBC (August 2014). In some embodiments, beam steering is performed by adjusting the power or phase of the ultrasonic waves emitted by the transducers in an array.
In some embodiments, the interrogator includes one or more of instructions for beam steering ultrasonic waves using one or more transducers, instructions for determining the relative location of one or more implantable devices, instructions for monitoring the relative movement of one or more implantable devices, instructions for recording the relative movement of one or more implantable devices, and instructions for deconvoluting backscatter from a plurality of implantable devices.
The implantable device and the interrogator wirelessly communicate with each other using ultrasonic waves. The implantable device receives ultrasonic waves from the interrogator through a miniaturized ultrasonic transducer on the implantable device. Vibrations of the miniaturized ultrasonic transducer on the implantable device generate a voltage across the electric terminals of the transducer and a current flows through the device, including the sensor and/or, if present, the ASIC.
Communication between the interrogator and the implantable device can use a pulse-echo method of transmitting and receiving ultrasonic waves. In the pulse-echo method, the interrogator transmits a series of interrogation pulses at a predetermined frequency, and then receives backscatter echoes from the implanted device. In some embodiments, the pulses are about 200 nanoseconds (ns) to about 1000 ns in length (such as about 300 ns to about 800 ns in length, about 400 ns to about 600 ns in length, or about 540 ns in length). In some embodiments, the pulses are about 100 ns or more in length (such as about 150 ns or more, 200 ns or more, 300 ns or more, 400 ns or more, 500 ns or more, 540 ns or more, 600 ns or more, 700 ns or more, 800 ns or more, 900 ns or more, 1000 ns or more, 1200 ns or more, or 1500 ns or more in length). In some embodiments, the pulses are about 2000 ns or less in length (such as about 1500 ns or less, 1200 ns or less, 1000 ns or less, 900 ns or less, 800 ns or less, 700 ns or less, 600 ns or less, 500 ns or less, 400 ns or less, 300 ns or less, 200 ns or less, or 150 ns or less in length). In some embodiments, the pulses are separated by a dwell time. In some embodiments, the dwell time is about 100 ns or more in length (such as about 150 ns or more, 200 ns or more, 300 ns or more, 400 ns or more, 500 ns or more, 540 ns or more, 600 ns or more, 700 ns or more, 800 ns or more, 900 ns or more, 1000 ns or more, 1200 ns or more, or 1500 ns or more in length). In some embodiments, the dwell time is about 2000 ns or less in length (such as about 1500 ns or less, 1200 ns or less, 1000 ns or less, 900 ns or less, 800 ns or less, 700 ns or less, 600 ns or less, 500 ns or less, 400 ns or less, 300 ns or less, 200 ns or less, or 150 ns or less in length). In some embodiments, the pulses are square, rectangular, triangular, sawtooth, or sinusoidal. In some embodiments, the pulses output can be two-level (GND and POS), three-level (GND, NEG, POS), 5-level, or any other multiple-level (for example, if using 24-bit DAC). In some embodiments, the pulses are continuously transmitted by the interrogator during operation. In some embodiments, when the pulses are continuously transmitted by the interrogator a portion of the transducers on the interrogator are configured to receive ultrasonic waves and a portion of the transducers on the interrogator are configured to transmit ultrasonic waves. Transducers configured to receive ultrasonic waves and transducers configured to transmit ultrasonic waves can be on the same transducer array or on different transducer arrays of the interrogator. In some embodiments, a transducer on the interrogator can be configured to alternatively transmit or receive the ultrasonic waves. For example, a transducer can cycle between transmitting one or more pulses and a pause period. The transducer is configured to transmit the ultrasonic waves when transmitting the one or more pulses, and can then switch to a receiving mode during the pause period. In some embodiments, the one or more pulses in the cycle includes about 1 to about 10 pulses (such as about 2 to about 8, or about 4 to about 7, or about 6) pulses of ultrasonic waves in any given cycle. In some embodiments, the one or more pulses in the cycle includes about 1 or more, 2 or more, 4 or more, 6 or more, 8 or more, or 10 or more pulses of ultrasonic waves in any given cycle. In some embodiments, the one or more pulses in the cycle includes about 20 or fewer, about 15 or fewer, about 10 or fewer, about 8 or fewer, or about 6 or fewer pulses in the cycle. The pulse cycle can be regularly repeated, for example every about 50 microseconds ([is) to about 300 [is (such as about every 75 [is to about 200 [is, or every about 100 [is) during operation. In some embodiments, the cycle is reaped every 50 [is or longer, every 100 [is or longer, every 150 [is or longer, every 200 [is or longer, every 250 [is or longer, or every 300 [is or longer. In some embodiments, the cycle is repeated every 300 [is or sooner, every 250 [is or sooner, every 200 [is or sooner, every 150 [is or sooner, or every 100 [is or sooner. The cycle frequency can set, for example, based on the distance between the interrogator and the implantable device and/or the speed at which the transducer can toggle between the transmitting and receiving modes.
The frequency of the ultrasonic waves transmitted by the transducer can be set depending on the drive frequency or resonant frequency of the miniaturized ultrasonic transducer on the implantable device. In some embodiments, the miniaturized ultrasonic transducers are broad-band devices. In some embodiments, the miniaturized ultrasonic transducers are narrowband. For example, in some embodiments the frequency of the pulses is within about 20% or less, within about 15% or less, within about 10% or less, within about 5% or less of the resonant frequency of the miniaturized ultrasonic transducer. In some embodiments, the pulses are set to a frequency about the resonant frequency of the miniaturized ultrasonic transducer. In some embodiments, the frequency of the ultrasonic waves is between about 100 kHz and about 100 MHz (such as between about 100 kHz and about 200 kHz, between about 200 kHz and about 500 kHz, between about 500 kHz and about 1 MHz, between about 1 MHz and about 5 MHz, between about 5 MHz and about 10 MHz, between about 10 MHz and about 25 MHz, between about 25 MHz and about 50 MHz, or between about 50 MHz and about 100 MHz). In some embodiments, the frequency of the ultrasonic waves is about 100 kHz or higher, about 200 kHz or higher, about 500 kHz or higher, about 1 MHz or higher, about 5 MHz or higher, about 10 MHz or higher, about 25 MHz or higher, or about 50 MHz or higher. In some embodiments, the frequency of the ultrasonic waves is about 100 MHz or lower, about 50 MHz or lower, about 25 MHz or lower, about 10 MHz or lower, about 5 MHz or lower, about 1 MHz or lower, about 500 kHz or lower, or about 200 kHz or lower. Higher frequency allows for a smaller miniaturized ultrasonic transducer on the implantable device. However, higher frequency also limits the depth of communication between the ultrasonic transducer and the implantable device. In some embodiments, the implantable device and the ultrasonic transducer are separated by about 0.1 cm to about 15 cm (such as about 0.5 cm to about 10 cm, or about 1 cm to about 5 cm). In some embodiments, the implantable device and the ultrasonic transducer are separated by about 0.1 cm or more, about 0.2 cm or more, about 0.5 cm or more, about 1 cm or more, about 2.5 cm or more, about 5 cm or more, about 10 cm or more, or about 15 cm or more. In some embodiments, the implantable device and the ultrasonic transducer are separated by about 20 cm or less, about 15 cm or less, about 10 cm or less, about 5 cm or less, about 2.5 cm or less, about 1 cm or less, or about 0.5 cm or less.
In some embodiments, the backscattered ultrasound is digitized by the implantable device. For example, the implantable device can include an oscilloscope or analog-to-digital converter (ADC) and/or a memory, which can digitally encode information in current (or impedance) fluctuations. The digitized current fluctuations, which reflect data sensed by the sensor, are received by the ultrasonic transducer, which then transmits digitized acoustic waves. The digitized data can compress the analog data, for example by using singular value decomposition (SVD) and least squares-based compression. In some embodiments, the compression is performed by a correlator or pattern detection algorithm. The backscatter signal may go through a series of non-linear transformation, such as 4th order Butterworth bandpass filter rectification integration of backscatter regions to generate a reconstruction data point at a single time instance. Such transformations can be done either in hardware (i.e., hard-coded) or in software.
In some embodiments, the digitized data can include a unique identifier. The unique identifier can be useful, for example, in a system comprising a plurality of implantable devices and/or an implantable device comprising a plurality of electrode pairs. For example, the unique identifier can identify the implantable device of signal origin when from a plurality of implantable devices. In some embodiments, an implantable device comprises a plurality of electrode pairs, which may simultaneously or alternatively receive electrophysiological signals that are detected by a single implantable device. Different pairs of electrodes, for example, can be configured to detect electrophysiological signals in different tissues (e.g., different nerves or different muscles) or in different regions of the same tissue. The digitized circuit can encode a unique identifier to identify which electrode pairs detected the electrophysiological signal.
In some embodiments, the digitized signal compresses the size of the analog signal. The decreased size of the digitized signal can allow for more efficient reporting of detected electrophysiological signals encoded in the ultrasonic backscatter. This can be useful, for example, when an implantable device includes a plurality of electrode pairs that simultaneously or approximately simultaneously detect an electrophysiological signal. By compressing the size of the electrophysiological signal through digitization, potentially overlapping signals can be accurately transmitted.
In some embodiments, an interrogator communicates with a plurality of implantable devices. This can be performed, for example, using multiple-input, multiple output (MIMO) system theory. For example, communication between the interrogator and the plurality of implantable devices using time division multiplexing, spatial multiplexing, or frequency multiplexing. In some embodiments, two or more (such as 3, 4, 5, 6, 7, 8, 9, 10 or more, 12 or more, about 15 or more, about 20 or more, about 25 or more, about 50 or more, or about 100 or more) implantable devices communicate with the interrogator. In some embodiments, about 200 or fewer implantable devices (such as about 150 or fewer, about 100 or fewer, about 50 or fewer, about 25 or fewer, about 20 or fewer, about 15 or fewer, about 12 or fewer, or about 10 or fewer implantable devices) are in communication with the interrogator. The interrogator can receive a combined backscatter from the plurality of the implantable devices, which can be deconvoluted, thereby extracting information from each implantable device. In some embodiments, interrogator focuses the ultrasonic waves transmitted from a transducer array to a particular implantable device through beam steering. The interrogator focuses the transmitted ultrasonic waves to a first implantable device, receives backscatter from the first implantable device, focuses transmitted ultrasonic waves to a second implantable device, and receives backscatter from the second implantable device. In some embodiments, the interrogator transmits ultrasonic waves to a plurality of implantable devices, and then receives ultrasonic waves from the plurality of implantable devices.
In some embodiments, the interrogator is used to determine the location or velocity of the implantable device. Velocity can be determined, for example, by determining the position or movement of a device over a period of time. The location of the implantable device can be a relative location, such as the location relative on the transducers on the interrogator. Knowledge of the location or movement of the implantable device allows for knowledge of the precise location of the electrophysiological signal detected in the tissue. By determining the location of the implantable device and associating the location with the detected electrophysiological signal, it is possible to characterize or monitor the tissue at a more localized point. A plurality of transducers on the interrogator, which may be disposed on the same transducer array or two or more different transducer arrays, can collect backscatter ultrasonic waves from an implantable device. Based on the differences between the backscatter waveform arising from the same implantable device and the known location of each transducer, the position of the implantable device can be determined. This can be done, for example by triangulation, or by clustering and maximum likelihood. The differences in the backscatter may be based on responsive backscatter waves, non-responsive backscatter waves, or a combination thereof.
In some embodiments, the interrogator is used to determine the location or velocity of the implantable device. Velocity can be determined, for example, by determining the position or movement of a device over a period of time. The location of the implantable device can be a relative location, such as the location relative on the transducers on the interrogator. Knowledge of the location or movement of the implantable device allows for knowledge of the precise location of the electrophysiological signal detected in the tissue. By determining the location of the implantable device and associating the location with the detected electrophysiological signal, it is possible to characterize or monitor the tissue at a more localized point. A plurality of transducers on the interrogator, which may be disposed on the same transducer array or two or more different transducer arrays, can collect backscatter ultrasonic waves from an implantable device. Based on the differences between the backscatter waveform arising from the same implantable device and the known location of each transducer, the position of the implantable device can be determined. This can be done, for example by triangulation, or by clustering and maximum likelihood. The differences in the backscatter may be based on responsive backscatter waves, non-responsive backscatter waves, or a combination thereof.
In some embodiments, the interrogator is used to track movement of the implantable device. Movement of the implantable device that can be tracked by the interrogator includes lateral and angular movement. Such movement may arise, for example, due to shifting of one or more organs such as the liver, stomach, small or large intestine, kidney, pancreas, gallbladder, bladder, ovaries, uterus, or spleen (which may be the result, for example, of respiration or movement of the subject) or variations in blood flow (such as due to a pulse). Thus, in some embodiments, the implantable device is useful for tracking movement of an organ or a pulse rate. Movement of the implantable device can be tracked, for example, by monitoring changes in the non-responsive backscatter waves. In some embodiments, movement of the implantable device is determined my comparing the relative location of the implantable device at a first time point to the relative location of the implantable device at a second time point. For example, as described above, the location of an implantable device can be determined using a plurality of transducers on the interrogated (which may be on a single array or on two or more arrays). A first location of the implantable device can be determined at a first time point, and a second location of the implantable device can be determined at a second time point, and a movement vector can be determined based on the first location at the first time point and the second location at the second time point.
In some embodiments, the implantable device includes a clock, which can be calibrated or synced by the interrogator. For example, the interrogator can transmit a signal using the transmitted ultrasonic waves that sets or syncs the clock. The signal can be simultaneously transmitted to a plurality of implantable devices, thereby syncing the clocks of the plurality of implantable devices. In some embodiments, backscatter from the implantable devices encodes a timestamp based on the clock, which can indicate the time (or relative time) of an event (such as encountered radiation). This can be useful, for example to compare two or more implantable devices and the relative time of encountering radiation.
The implantable devices are miniaturized, which allows for comfortable and long-term implantation while limiting tissue inflammation that is often associated with implantable devices. The body forms the core of the miniaturized implantable device (e.g., the ultrasonic transducer and the integrated circuit), and the electrodes branch from the body and engage the tissue to deliver an electrical pulse to stimulate the tissue. In some embodiments, the longest dimension of the implantable device or the body of the implantable device is about 5 mm or less, about 4 mm or less, about 3 mm or less, about 2 mm or less, about 1 mm or less, about 0.5 mm or less, or about 0.3 mm or less in length. In some embodiments, the longest dimension of the implantable device or body of the implantable device is about 0.2 mm or longer, about 0.5 mm or longer, about 1 mm or longer, about 2 mm or longer, or about 3 mm or longer in the longest dimension of the device. In some embodiments, the longest dimension of the implantable device or the body of the implantable device is about 0.2 mm to about 5 mm in length, about 0.3 mm to about 4 mm in length, about 0.5 mm to about 3 mm in length, about 1 mm to about 3 mm in length, or about 2 mm in length.
In some embodiments, one or more of the electrodes are on the body of the device, for example a pad on the body of the device. In some embodiments, one or more of the electrodes extend from the body of the implantable device at any desired length, and can be implanted at any depth within the tissue. In some embodiments, an electrode is about 0.1 mm in length or longer, such as about 0.2 mm or longer, about 0.5 mm or longer, about 1 mm in length or longer, about 5 mm in length or longer, or about 10 mm in length or longer. In some embodiments, the electrodes are about 15 mm or less in length, such as about 10 mm or less, about 5 mm or less, about 1 mm or less, or about 0.5 mm or less in length. In some embodiments, the first electrode is disposed on the body of the implantable device and the second electrode extends from the body of the implantable device.
In some embodiments, the implantable device has a volume of about 5 mm or less (such as about 4 mm 3 or less, 3 mm 3 or less, 2 mm 3 or less, or 1 mm 3 or less). In certain embodiments, the implantable device has a volume of about 0.5 mm 3 to about 5 mm 3, about 1 mm 3 to about 5 mm 3, about 2 mm 3 to about 5 mm 3, about 3 mm 3 to about 5 mm 3, or about 4 mm 3 to about 5 mm. The small size of the implantable device allows for implantation of the device using a biopsy needle.
In some embodiments, the implantable device is implanted in a subject. The subject can be for example, an animal, such as a mammal. In some embodiments, the subject is a human, dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, rat, or mouse. In some embodiments, the subject is a plant. Implantable devices implanted in plants can be useful, for example, for monitoring conditions of agricultural plants.
In some embodiments, the implantable device or a portion of the implantable device (such as the miniaturized ultrasonic transducer and the integrated circuit) is encapsulated by a biocompatible material (such as a biocompatible polymer), for example a copolymer of N-vinyl-2-pyrrolidinone (NVP) and n-butylmethacrylate (BMA), polydimethylsiloxane (PDMS), parylene, polyimide, silicon nitride, silicon dioxide, silicon carbide, alumina, niobium, or hydroxyapatite. The silicon carbide can be amorphous silicon carbide or crystalline silicon carbide. The biocompatible material is preferably impermeable to water to avoid damage or interference to electronic circuitry within the device. In some embodiments, the implantable device or portion of the implantable device is encapsulated by a ceramic (for example, alumina or titania) or a metal (for example, steel or titanium). In some embodiments, the electrodes or a portion of the electrodes are not encapsulated by the biocompatible material.
In some embodiments, the miniaturized ultrasonic transducer and the ASIC are disposed on a printed circuit board (PCB). The electrodes can optionally be disposed on the PCB, or can otherwise be connected to the integrated circuit.
The miniaturized ultrasonic transducer of the implantable device can be a bulk piezoelectric transducer. Bulk piezoelectric transducers can be any natural or synthetic material, such as a crystal, ceramic, or polymer. Exemplary bulk piezoelectric transducer materials include barium titanate (BaTiO3), lead zirconate titanate (PZT), zinc oxide (ZO), aluminum nitride (AlN), quartz, berlinite (AlPO4), topaz, langasite (La3Ga5SiOi4), gallium orthophosphate (GaPO4), lithium niobate (LiNbO3), lithium tantalite (LiTaO3), potassium niobate (KNbO3), sodium tungstate (Na2WO3), bismuth ferrite (BiFeO3), polyvinylidene (di)fluoride (PVDF), and lead magnesium niobate-lead titanate (PMN-PT).
In some embodiments, the miniaturized bulk piezoelectric transducer is approximately cubic (i.e., an aspect ratio of about 1:1:1 (length:width:height). In some embodiments, the piezoelectric transducer is plate-like, with an aspect ratio of about 5:5:1 or greater in either the length or width aspect, such as about 7:5:1 or greater, or about 10:10:1 or greater. In some embodiments, the miniaturized bulk piezoelectric transducer is long and narrow, with an aspect ratio of about 3:1:1 or greater, and where the longest dimension is aligned to the direction of propagation of the carrier ultrasound wave. In some embodiments, one dimension of the bulk piezoelectric transducer is equal to one half of the wavelength (A) corresponding to the drive frequency or resonant frequency of the transducer. At the resonant frequency, the ultrasound wave impinging on either the face of the transducer will undergo a 180° phase shift to reach the opposite phase, causing the largest displacement between the two faces. In some embodiments, the height of the piezoelectric transducer is about 10μπι to about 1000μπι (such as about 40μπι to about 400μπι, about 100μπι to about 250μπι, about 250μπι to about 500μπι, or about 500μπι to about 1000μπι). In some embodiments, the height of the piezoelectric transducer is about 5 mm or less (such as about 4 mm or less, about 3 mm or less, about 2 mm or less, about 1 mm or less, about 500μπι or less, about 400μπι or less, 250μπι or less, about 100μπι or less, or about 40μπι or less). In some embodiments, the height of the piezoelectric transducer is about 20μπι or more (such as about 40μπι or more, about 100μπι or more, about 250μπι or more, about 400μπι or more, about 500μπι or more, about 1 mm or more, about 2 mm or more, about 3 mm or more, or about 4 mm or more) in length.
In some embodiments, the ultrasonic transducer has a length of about 5 mm or less such as about 4 mm or less, about 3 mm or less, about 2 mm or less, about 1 mm or less, about 500μπι or less, about 400μπι or less, 250μπι or less, about 100μπι or less, or about 40μπι or less) in the longest dimension. In some embodiments, the ultrasonic transducer has a length of about 20μπι or more (such as about 40μπι or more, about 100μπι or more, about 250μπι or more, about 400μπι or more, about 500μπι or more, about 1 mm or more, about 2 mm or more, about 3 mm or more, or about 4 mm or more) in the longest dimension.
The miniaturized ultrasonic transducer is connected two electrodes; the first electrode is attached to a first face of the transducer and the second electrode is attached to a second face of the transducer, wherein the first face and the second face are opposite sides of the transducer along one dimension. In some embodiments, the electrodes comprise silver, gold, platinum, platinum-black, poly(3,4-ethylenedioxythiophene (PEDOT), a conductive polymer (such as conductive PDMS or polyimide), or nickel. In some embodiments, the transducer is operated in shear-mode where the axis between the metallized faces (i.e., electrodes) of the transducer is orthogonal to the motion of the transducer.
The implantable devices can be manufactured by attaching a miniaturized ultrasonic transducer (such as a bulk piezoelectric transducer) to a first electrode on a first face of the piezoelectric transducer, and a second electrode to a second face of the piezoelectric transducer, wherein the first face and the second face are on opposite sides of the piezoelectric transducer. The first electrode and the second electrode can be attached to an application-specific integrated circuit (ASIC), which may be disposed on a printed circuit board (PCB). Attachment of the components to the PCB can include wirebonding, soldering, flip-chip bonding, or gold bump bonding. The ASIC can include one or more sensors.
Certain piezoelectric materials can be commercially obtained, such as metalized PZT sheets of varying thickness (for example, PSI-5A4E, Piezo Systems, Woburn, Mass., or PZT 841, APC Internationals, Mackeyville, Pa.). In some embodiments, a piezoelectric material sheet is diced into a desired size, and the diced piezoelectric material is attached to the electrodes. In some embodiments, the electrodes are attached to the piezoelectric material sheet, and the piezoelectric material sheet is diced to the desired size with the electrodes attached to the piezoelectric material. The piezoelectric material can be diced using a dicing saw with a ceramic blade to cut sheets of the piezoelectric material into individualized piezoelectric transducer. In some embodiments, a laser cutter is used to dice or singulate the piezoelectric material. In some embodiments, patterned etching is used to dice or singulate the piezoelectric material.
Electrodes can be attached to the top and bottom of the faces of the piezoelectric transducers, with the distance between the electrodes being defined as the height of the piezoelectric transducer. Exemplary electrodes can comprise one or more of silver, gold, platinum, platinum-black, poly(3,4-ethylenedioxythiophene (PEDOT), a conductive polymer (such as conductive PDMS or polyimide), or nickel. In some embodiments, the electrode is attached to the piezoelectric transducer by electroplating or vacuum depositing the electrode material onto the face of the piezoelectric transducer. In some embodiments, the electrodes are soldered onto the piezoelectric transducer using an appropriate solder and flux. In some embodiments, the electrodes are attached to the piezoelectric transducer using an epoxy (such as a silver epoxy) or low-temperature soldering (such as by use of a solder paste).
In an exemplary embodiment, solder paste is applied to a pad on a printed circuit board (PCB), either before or after the ASIC is attached to the PCB. The size of the pad on the circuit board can depend on the desired size of the piezoelectric transducer. Solely by way of example, if the desired size of piezoelectric transducer is about 100μπι×100μπι×100μπι, the pad can be about 100μπι×100μπι. The pad functions as the first electrode for the implantable device. A piezoelectric material (which may be larger than the pad) is placed on the pad, and is held to the pad by the applied solder paste, resulting in a piezoelectric-PCB assembly. The piezoelectric-PCB assembly is heated to cure the solder paste, thereby bonding the piezoelectric transducer to the PCB. If the piezoelectric material is larger than the pad, the piezoelectric material is cut to the desired size, for example using a wafer dicing saw or a laser cutter. Non-bonded portions of the piezoelectric material (for example, the portions of the piezoelectric material that did not overlay the pad) are removed. A second electrode is attached to the piezoelectric transducer and the PCB, for example by forming a wirebond between the top of the piezoelectric transducer and the PCB, which completes the circuit. The wirebond is made using a wire made from any conductive material, such as aluminum, copper, silver, or gold.
The integrated circuit and the miniaturized ultrasonic transducer can be attached on the same side of the PCB or on opposite sides of the PCB. In some embodiments, the PCB is a flexible PCB, the integrated circuit and the ultrasonic transducer are attached to the same side of the PCB, and the PCB is folded, resulting in an implantable device in which the integrated circuit and the ultrasonic transducer are on opposite sides of the PCB.
Optionally, the device or a portion of the device is encapsulated in or a portion of the device is encapsulated in a biocompatible material (such as a biocompatible polymer), for example a copolymer of N-vinyl-2-pyrrolidinone (NVP) and n-butylmethacrylate (BMA), polydimethylsiloxane (PDMS, e.g., Sylgard 184, Dow Corning, Midland, Mich.), parylene, polyimide, silicon nitride, silicon dioxide, alumina, niobium, hydroxy apatite, or silicon carbide. The silicon carbide can be amorphous silicon carbide or crystalline silicon carbide. In some embodiments, the biocompatible material (such as amorphous silicon carbide) is applied to the device by plasma enhanced chemical vapor deposition (PECVD) or sputtering. PECVD may use precursors such as S1H4 and CH4 to generate the silicon carbide. In some embodiments, the implantable device or portion of the implantable device is encased in a ceramic (for example, alumina or titania) or a metal (for example, steel or titanium) suitable for medical implantation.
Optionally, the ASIC is coated with additional solder. At step 904, a piezoelectric transducer (the “piezo” in
Similarly, the piezoelectric transducer may be wirebonded to the PCB either before or after attachment or wirebonding of the ASIC to the PCB. At step 908, at least a portion of the device is coated with a biocompatible material. Preferably, at least the piezoelectric transducer and the ASIC are coated with the biocompatible material. In some embodiments, the sensor is not or at least a portion of the sensor is not coated with the biocompatible material. For example, in some embodiments, the implantable device comprises a pair of electrodes which are not coated with the biocompatible material, which allows the electrodes to detect an electrophysiological signal. In some embodiments, the biocompatible material is cured, for example by exposure to UV light or by heating.
In some embodiments, the implantable device or a portion of the implantable device is encapsulated in an amorphous silicon carbide (a-SiC) film.
In contrast,
Accordingly, based on the data shown in
The resonator Q is defined as the ratio of energy stored to energy dissipated per oscillation period. To achieve high Q in resonators, energy dissipation (loss) should be minimized. Energy loss in piezo resonators generally results from fluid damping, anchor loss, and intrinsic loss (loss within the crystal itself). Among these loss mechanisms, fluid damping, causing energy loss from the piezo to the fluid, can dominate for piezos operated in aqueous environments. Here, the piezos were tested in water, which has an acoustic impedance similar to soft tissue (˜1.5 MRayls). To minimize the effect of fluid damping on the piezo Q, the crystal sidewalls were isolated from the liquid environment using the housing shown in
Minimizing fluid damping allowed for the identification of the effect of the other dominant source of energy loss, which is anchor loss, on the piezo Q. Anchor loss is the result of mechanical wave propagation from the anchor into the substrate. In existing ultrasonic implants, the piezocrystal is directly attached to the package substrate through an anchor (electrode) that completely covers the piezo bottom surface, making the piezo strongly coupled to the substrate and hence resulting in high anchor loss. In contrast, small anchors rather than a single large anchor are used here. The anchors were attached to the piezo regions that exhibited the minimum deformation during operation. An FEM simulation of the principal mode when operating a piezo with a bulk excitation normal to the top and bottom of a fixed-free piezocrystal shows that the largest deformation occurs at the center of the piezo bottom and top surfaces (
The normalized admittance curves measured in air (
Here, the piezocrystal operates in the 33-mode as the direction of mechanical strain induced by acoustic pressure waves is identical to the electrical polarization direction (perpendicular to the surface electrodes). The piezo response to the excitation force F(t) in the longitudinal z-direction can be modeled by the following governing equations:
where z(t), meq, ωr, and Qr are the piezo's longitudinal displacement at time t, equivalent effective mass, resonance frequency, and quality factor at resonance. The dot represents the time derivative, νp(t) is the voltage across the piezo, θ is the electromechanical coupling term, Cp is the piezo internal capacitance, and Zcir is the electrical load impedance. Equations 1 and 2 describe the mechanical and electrical behaviors of the piezo, respectively; these two domains are electromechanically coupled through the coupling term θ (
By substituting z(t)=zejωt, νp(t)=νpejωt and F(t)=Fejωt into equations 1 and 2, solving these equations simultaneously at steady state, and rearranging the terms, the electrical power delivered to Rcir can be obtained as
where keq is the equivalent stiffness, determining the piezo ωr=√{square root over (keq/meq)}, and dimensionless terms are defined: κ2=θ/(Cpkeq) is the system coupling term, α=ωrRcirCp and γ=ωrRcirCcir are the time constants, and {tilde over (ω)}=ω/ωr is the normalized excitation frequency. The power harvesting efficiency of the piezo is defined as: η=Pout/Pin, where Pin is the total acoustic power at the piezo surface that equals p2/(ρ0c0)×A−ρ0 and c0 are the density and sound velocity of the medium.
To provide a better understanding of piezo performance, we also analyze the impedance matching efficiency between the piezo and the electrical load, nmatch=Pout/Pav,el, where Pav,el is the available electrical power in the system. The Thevenin equivalent circuit model of the piezo (
ηmatch can be derived using equation 4 as
The piezocrystals were characterized in a water tank setup (
revealing that the parameters that determine the Rcir,opt for achieving ηmax and nmatch,max appear different. Therefore, the ηmax and nmatch, max may occur at different Rcir,opt for the piezo operated at ωr (
The backscatter amplitude modulation is achieved by changing the load impedance (Zcir) as the acoustic reflection coefficient Γ at the piezo boundary is a function of Zcir, that is Pr=Γ(Zcir)2×Pin, where Pr is the reflected acoustic power from the piezo surface. The maximum modulation depth, defined as the ratio of the amplitude difference between the modulated and unmodulated signals to the unmodulated signal, is obtained at resonance (ωr). Here, the effect of system parameters on Γ at ωr were investigated for the piezos with different anchor sizes and different Rcir values. The Γ can be predicted at or using its Thevenin equivalent circuit model (
where ZL=Zcir∥Cp. Equation 6 reveals that Γ depends on not only Rcir (through α and γ), but also quality factor Qr and system coupling term κ2.
where Vb is the backscatter signal detected by the external transducer. As Rcir increases, Γ approaches 1 for the strongly coupled, high-Qr piezo, but it is not able to reach 1 for the weakly coupled, low-Qr piezo. The individual effect of Qr and κ2 on Γ at ωr is demonstrated in
Accordingly, an attachment method for piezocrystals used in mm- and sub-mm scale medical implants is provided herein. The method relies on placing small anchors at piezocrystal regions where the excited mode displacement is minimal; this approach reduces anchor loss, maximizing the piezocrystal's Q-factor. The results of this study also indicate that the use of small anchors maximizes system coupling. The study further shows that the strongly coupled high-Q piezo with small corner electrodes achieves ˜10× higher power harvesting efficiency η (˜48%) at resonance than that of a piezo with a single electrode (covering all of the bottom side of the piezocrystal), operated at the same excitation frequency (
Furthermore, when implemented, any of the methods and techniques described herein or portions thereof may be performed by executing software stored in one or more non-transitory, tangible, computer readable storage media or memories such as magnetic disks, laser disks, optical discs, semiconductor memories, biological memories, other memory devices, or other storage media, in a RAM or ROM of a computer or processor, etc.
Of course, the applications and benefits of the systems, methods and techniques described herein are not limited to only the above examples. Many other applications and benefits are possible by using the systems, methods and techniques described herein.
Embodiment 1. An implantable device, comprising: a substrate; an integrated circuit attached to the substrate; and an ultrasonic transducer configured to receive ultrasonic waves that power the integrated circuit, wherein the ultrasonic transducer is attached to the substrate via one or more electrodes, and wherein the total electrode surface area in contact with the ultrasonic transducer is smaller than the surface area of a face of the ultrasonic transducer to which the one or more electrodes are attached.
Embodiment 2. The implantable device of Embodiment 1, wherein the one or more electrodes are each positioned at a respective corner of the face of the ultrasonic transducer to which the one or more electrodes are attached.
Embodiment 3. The implantable device of Embodiment 1 or Embodiment 2, wherein the one or more electrodes are each positioned at an edge of the face of the ultrasonic transducer to which the one or more electrodes are attached.
Embodiment 4. The implantable device of any of Embodiments 1-3, wherein the one or more electrodes comprise a single electrode positioned at a center of the face of the ultrasonic transducer to which the single electrode is attached.
Embodiment 5. The implantable device of any of Embodiments 1-4, wherein the one or more electrodes include an electrode having an opening between the face of the ultrasonic transducer and the substrate.
Embodiment 6. The implantable device of any of Embodiments 1-5, wherein the ultrasonic transducer has a cubic shape.
Embodiment 7. The implantable device of any of Embodiments 1-6, wherein the ultrasonic transducer has a rectangular prism shape.
Embodiment 8. The implantable device of any of Embodiments 1-7, wherein the face of the ultrasonic transducer to which the one or more electrodes are attached has a rectangular shape.
Embodiment 9. The implantable device of any of Embodiments 1-8, wherein a ratio of a length of each of the one or more electrodes to a length of the face of the ultrasonic transducer to which the one or more electrodes are attached is less than 0.1.
Embodiment 10. The implantable device of any of Embodiments 1-9, wherein a ratio of a length of each of the one or more electrodes to a length of the face of the ultrasonic transducer to which the one or more electrodes are attached is less than 0.2.
Embodiment 11. The implantable device of any of Embodiments 1-10, wherein the ultrasonic transducer is further configured to emit an ultrasonic backscatter.
Embodiment 12. The implantable device of any of Embodiments 1-11, wherein the ultrasonic transducer is configured to receive the ultrasonic waves from an interrogator comprising one or more additional ultrasonic transducers.
Embodiment 13. The implantable device of any of Embodiments 1-12, wherein the ultrasonic transducer is a bulk piezoelectric transducer.
Embodiment 14. The implantable device of any of Embodiments 1-13, wherein the implantable device is implanted in a subject.
Embodiment 15. The implantable device of any of Embodiments 14, wherein the subject is a human.
Embodiment 16. The implantable device of Embodiment 14 or Embodiment 15, wherein the subject is an animal or a plant.
Embodiment 17. The implantable device of any of Embodiments 1-16, wherein the implantable device is about 5 mm or less in length in the longest dimension.
Embodiment 18. The implantable device of any of Embodiments 1-17, wherein the implantable device has a volume of about 5 mm or smaller.
Embodiment 19. The implantable device of any of Embodiments 1-18, wherein the implanted device is at least partially encapsulated by a biocompatible material.
Embodiment 20. A system comprising one or more implantable devices according to any of Embodiments 1-19, and an interrogator comprising one or more ultrasonic transducers configured to transmit ultrasonic waves to the one or more implantable devices or receive ultrasonic backscatter from the one or more implantable devices.
Embodiment 21. The system of Embodiment 20, wherein the interrogator comprises one or more ultrasonic transducer arrays, wherein each transducer array comprises two or more ultrasonic transducers.
Embodiment 22. The system of Embodiment 20 or Embodiment 21, wherein the system comprises a plurality of implantable devices.
Embodiment 23. The system of any of embodiments 20-22, wherein the interrogator is configured to beam steer transmitted ultrasonic waves to alternatively focus the transmitted ultrasonic waves on a first portion of the plurality of implantable devices or focus the transmitted ultrasonic waves on a second portion of the plurality of implantable devices.
Embodiment 24. The system of any of embodiments 20-23, wherein the interrogator is configured to simultaneously receive ultrasonic backscatter from at least two implantable devices.
Embodiment 25. The system of any of embodiments 20-24, wherein the interrogator is configured to transit ultrasonic waves to the plurality of implantable devices or receive ultrasonic backscatter from the plurality of implantable devices using time division multiplexing, spatial multiplexing, or frequency multiplexing.
Embodiment 26. The system of any of embodiments 20-25, wherein the interrogator is configured to be wearable by a subject.
The present application claims priority to U.S. Provisional Patent Application No. 62/978,520, filed Feb. 19, 2020, entitled “ANCHOR LOSS IN MILLIMETER-SCALE ULTRASONIC WIRELESS IMPLANTABLE DEVICES,” the disclosure of which is incorporated herein by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2021/018644 | 2/19/2021 | WO |
Number | Date | Country | |
---|---|---|---|
62978520 | Feb 2020 | US |